- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06910969
Flerfaglig intervensjon for voksne med kronisk graft-versus-vert sykdom (HORIZONS)
Multi-site randomisert kontrollert studie av et flerfaglig intervensjon for voksne med kronisk transplantat kontra vertssykdom
The goal of this study is to demonstrate the efficacy of a multidisciplinary group-based telehealth intervention (HORIZONS) compared to minimally enhanced usual care for improving self-management and quality of life for hematopoietic stem cell transplant (HSCT) survivors living with chronic graft-versus host disease, and to identify critical facilitators and barriers for HORIZONS implementation and adoption.
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
This is a randomized clinical trial to determine whether a multidisciplinary group-based telehealth intervention is effective at improving the quality of life and reducing psychosocial distress in patients living with chronic graft-versus-host disease. The HORIZONS intervention was developed with the goal of improving the experience and needs of patients living with chronic graft-versus-host disease.
Participants will be randomized into one of the two study groups: HORIZONS plus usual care or minimally enhanced usual care.
Participation in this study is expected to last up to 18 weeks after enrollment.
The investigators expect that about 350 adult allogeneic hematopoietic cell transplant recipients with moderate to severe chronic graft versus host disease will take part in this research study.
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Lara Traeger PhD
- Telefonnummer: 304-284-3012
- E-post: ltraeger@miami.edu
Studer Kontakt Backup
- Navn: Areej El-Jawahri MD
- Telefonnummer: 617-721-4000
- E-post: ael-jawahri@mgb.org
Studiesteder
-
-
Florida
-
Miami, Florida, Forente stater, 33136
- Rekruttering
- University of Miami Sylvester Comprehensive Cancer Center
-
Hovedetterforsker:
- Lara Traeger, PhD
-
Ta kontakt med:
- Lara Traeger, PhD
- Telefonnummer: 305-243-5302
- E-post: ltraeger@miami.edu
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02114
- Rekruttering
- Massachusetts General Hospital
-
Hovedetterforsker:
- Areej El-Jawahri, MD
-
Ta kontakt med:
- Areej El-Jawahri
- Telefonnummer: 617-724-4000
- E-post: ael-jawahri@mgb.org
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Adult patients (≥ 18 years) who have undergone allogeneic HCT
- Have moderate to severe cGVHD based on patient-report
- Have ability to participate in English or Spanish language group telehealth intervention.
Exclusion Criteria:
- Patients with mild cGVHD based on their self-report.
- Patients with a major untreated psychiatric or cognitive condition which the treating oncology clinicians believes interferes with the capacity to provide informed consent.
- Patients with active relapsed disease requiring therapy.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Støttende omsorg
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: HORIZONS intervention
Participants randomized to HORIZONS plus usual care will complete the following:
|
Therapist-delivered multidisciplinary group-based telehealth intervention comprised of 8 sessions |
|
Aktiv komparator: Minimally enhanced usual care
Participants randomized to usual care will complete the following
|
Receiving a standardized booklet with evidence-based information on chronic GHVD management and HST survivorship recommendations |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Patient quality of life (QOL) as measured by the Functional Assessment of Cancer Therapy-BMT (FACT-BMT) questionnaire
Tidsramme: At 10 weeks post-enrollment
|
Compare patient QOL as measured by the FACT-BMT between the two study groups. The FACT-BMT ranges from 0-164 with higher scores indicating better QOL |
At 10 weeks post-enrollment
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Patient depression symptoms as measured by the Hospital Anxiety and Depression Scale (HADS-Depression)
Tidsramme: At 10 weeks post enrollment
|
Compare depression symptoms as measured by the HADS-Depression between the study groups. The HADS-Depression ranges from 0-21 with higher scores indicating worse depression symptoms |
At 10 weeks post enrollment
|
|
Patient anxiety symptoms as measured by the Hospital Anxiety and Depression Scale (HADS-Anxiety)
Tidsramme: At 10 weeks post enrollment
|
Compare anxiety symptoms as measured by the HADS-Anxiety between the study groups. The HADS-Anxiety ranges from 0-21 with higher scores indicating worse anxiety symptoms. |
At 10 weeks post enrollment
|
|
Patient chronic graft-versus-host disease symptoms as measured with the Lee Symptom Scale
Tidsramme: At 10 weeks post enrollment
|
Compare chronic graft versus host disease symptoms as measured by the Lee Symptom Scale. The Lee Symptom Scale ranges from 0 -100 with higher scores indicating worse symptomatology |
At 10 weeks post enrollment
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Areej El-Jawahri MD, Massachusetts General Hospital
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 24-651
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
The Dana Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to Areej El-Jawahri (ael-jawahri@mgb.org). The protocol and statistical analysis plan will be made available on Clinicaltrials.gov as required by federal regulation or as a condition of awards and agreements supporting the research.
IPD-delingstidsramme
Data can be shared no earlier than 1 year following the date of publication
Tilgangskriterier for IPD-deling
Contact the Partners Innovations team at http://www.partners.org/innovation
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
- SEVJE
- ICF
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .